by The global anatomic pathology market size is expected to be worth around US$ 40.66 billion by 2030, according to a new report by Vision Research Reports.
The global anatomic pathology market size was valued at US$ 17.06 billion in 2020 and is anticipated to grow at a CAGR of 11.08% during forecast period 2021 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38913
Table of Contents
Anatomic Pathology Market Growth Factors
The advent of technology in the instruments and the protocols used during the anatomic pathological procedures is anticipated to increase the adoption rate of advanced anatomic pathological instruments.
The drug discovery and development application segment are expected to witness the fastest growth over the forecast period due to the shifting paradigm from conventional medicine to personalized medicine. This is primarily due to the growing reliance on discoveries of putative biomarkers for the development of personalized therapies.
Anatomic Pathology Market Report Coverage
| Report Scope | Details |
| Market Size | US$ 40.66 Billion by 2030 |
| Growth Rate | CAGR of 11.08% From 2021 to 2030 |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Product & services, Application, End-use |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Danaher Corporation; PHC Holdings Corporation; Quest Diagnostics Incorporated; Laboratory Corporation of America Holdings; F. Hoffmann-La Roche AG; Agilent Technologies, Inc.; Cardinal Health; Sakura Finetek USA, Inc.; NeoGenomics Laboratories, Inc.; BioGenex; Bio SB |
By Product & Services Analysis
The consumables segment dominated the market in 2020 with a share of over 65.0%. The availability of a wide range of products, coupled with a high usage rate of consumables in research findings, is fueling the segment growth.
A substantial number of reagents and kits, antibodies, and probes are being marketed for anatomic pathology protocols.The ongoing technological advancements and focused efforts by the market participants to offer anatomic pathological instruments with an improved design are anticipated to bolster the growth of the instruments segment.
By Application Analysis
The disease diagnosis segment accounted for the largest share of over 55.0% in 2020. Pathology protocols provide an opportunity for researchers to explore disease etiology and associated outcomes.
The anatomic pathology workflow aids the detection of a tumor at the inflammatory and proliferating stromal cells stage, thus minimizing costs associated with tumor eradication.
The drug discovery and development segment is anticipated to grow at a lucrative pace over the forecast period. Tissue analysis carried out by the pathologists generates a wealth of information for pharmaceutical manufacturers during preclinical trials.
By End-use Analysis
The hospitals’ segment dominated the market with a revenue share of over 45.0% in 2020 owing to the high hospitalization rate of cancer patients, coupled with a substantial number of frequent readmissions in hospitals.
The hospitals segment is also expected to be befitted by an increasing number of initiatives undertaken by the public and private agencies to promote advanced healthcare systems.
A large number of clinical trials through various ongoing projects spurs the growth of the research laboratories segment.
By Regional Analysis
North America accounted for the largest revenue share of over 45.0% in 2020 due to the presence of major players and supportive government initiatives pertaining to training pathological programs.
Spiraling demand for advanced imaging modalities, an increase in better patient care facilities, and several pathology laboratories franchising their presence fuels the growth of the Asia Pacific market.
Read also @ Endoscopy Devices Market to Reach US$ 72.9 Billion by 2030
Major Key Players Covered in The Anatomic Pathology Market Report include
- Danaher Corporation
- PHC Holdings Corporation
- Quest Diagnostics Incorporated
- Laboratory Corporation of America Holdings
- F. Hoffmann-La Roche AG
- Agilent Technologies, Inc.
- Cardinal Health
- Sakura Finetek USA, Inc.
- NeoGenomics Laboratories, Inc.
- BioGenex
- Bio SB
Anatomic Pathology Market Segmentation
- By Product & Services
- Instruments
- Microtomes & Cryostat
- Tissue Processors
- Automatic Stainers
- Whole Slide Imaging (WSI) Scanners
- Other Products
- Consumables
- Reagents & Antibodies
- Probes & Kits
- Others
- Services
- Instruments
- By Application
- Disease Diagnosis
- Drug Discovery and Development
- Others
- By End-use
- Hospitals
- Research Laboratories
- Diagnostic Laboratories
- Others
- Regional
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Asia Pacific
- China
- India
- Latin America
- Brazil
- Mexico
- Middle East and Africa (MEA)
- South Africa
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Anatomic Pathology Market Snapshot
Chapter 4. Anatomic Pathology Market Variables and Scope
4.1. Introduction
4.2. Anatomic Pathology Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Anatomic Pathology Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Anatomic Pathology Market, By Product
7.1. Anatomic Pathology Market, by Product, 2021-2030
7.1.1. Instruments
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Consumables
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Services
7.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Anatomic Pathology Market, By Application
8.1. Anatomic Pathology Market, by Application, 2021-2030
8.1.1. Disease Diagnosis
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Drug Discovery and Development
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Anatomic Pathology Market, By End User
9.1. Anatomic Pathology Market, by End User, 2021-2030
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Research Laboratories
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Diagnostic Laboratories
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Diagnostic Laboratories
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Anatomic Pathology Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.3. Market Revenue and Forecast, by End User (2017-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.5.3. Market Revenue and Forecast, by End User (2017-2030)
Chapter 11. Company Profiles
11.1. Danaher Corporation
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. PHC Holdings Corporation
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Quest Diagnostics Incorporated
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Laboratory Corporation of America Holdings
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. F. Hoffmann-La Roche AG
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Agilent Technologies, Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Cardinal Health
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Sakura Finetek USA, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. NeoGenomics Laboratories, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. BioGenex
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38913
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
